Meeting Highlights from 2nd Annual Heart iN Diabetes Medical Conference

July 13-15, 2018
Loew's Philadelphia Hotel
1200 Market Street
Philladelphia, PA

This 3-day intensive program, coordinated by the Metabolic Institute of America, focused on two concomitant conditions—diabetes and cardiovascular disease— that intersect, co-exist, and increasingly require co-management. 

Patients will benefit from endocrinologists and primary care practitioners who are well prepared to address the full body impact manifesting in a myriad of medical complications that develop from the dual presence of doabetes and CVD. 

Th aim of this program was to heighten attention to the emerging interconnectedness of diabetes, heart disease, and kidney disorders. Adding to the more well known macrovascular and microvascular complications, lung diabetes and cancers are now recognized as arising with co-morbid type 2 diabetes (T2D) and cardiovascular disease (CVD), and you'll begin to appreciate the need to initiate treatment earlier and more aggressively. 

In fact, endocrinologists and primary care practitioners can no longer expect to simply refer patiently on an as needed basis to cardiologists. Rather,  when treating patients with diabetes, it is now a necessity that clinical management planning takes into consideration the implications of CVD in selecting medications and in considering desired outcomes.

Given that most of these patients have obesity in conjunction with type 2 diabetes and cardiovascular disease, the management strategies needed to reduce the myriad of risk factors and provide optimal care must consider the impact that treatment has on every organ in the body.

EndocrineWeb was in attendance to learn more about the opportunities for prevention and advances in treatment in order to share the insights of the internationally recognized leaders in diabetes and cardiovascular disease.

Of particular interest, we share exclusive EndocrineWeb video interviews of the following experts:

Yehuda Handelsman, MD, Medical Director of the Metabolic Institute of America in California, which coordinated the Heart in Diabetes program, meeting co-chair Dr. Handlesman, stressed the urgency with which endocrinologists and primary care provides must consider the full array of concomitant cardiovascular challenges facing people with diabetes and be prepared to manage these patients earlier and more aggressive to prevent or forestall adverse outcomes both microvascular and macrovascular which affect every organ in the body.

Mikhail N. Kosiborad, MD, professor of medicine at the University of Missouri-Kansas City, as meeting co-chair he made a compelling case for bringing together specialists in diabetes and cardiology to address chronic heart failure and other aspects of CVD for optimal management.

George L. Bakris, MD, professor of medicine at the University of Chicago School of Medicine and chair of the Hypertension Center, discusses the goals for blood pressure control, specifically in patients with diabetes who are at increased risk for cardiovascular disease. He offered a reasoned view for less stringent blood pressure ranges but focused as much on the need for clinicians to reassess and redouble their efforts to meet the protocol for taking accurate blood pressures without which the goals and guidelines are ineffective and treatment is likely inappropriate or worse, harmful.       

Zachary T. Bloomgarden, MD, clinical professor of medicine at the Icahn School of Medicine at Mount Sinai who offered a case for Why Clinicians Should Prescribe SGLT2is for People with Diabetes? In reviewing the evidence for cardiovascular outcomes, renal outcomes, and most specifically adherence, Dr. Bloomgarden made a compelling argument for the use of SGLT2s in most patients with type 2 diabetes.

Richard E. Pratley, MD, medical director at the Florida Diabetes Hospital Diabetes Institute in Orlando, Florida, argued in favor of GLP1-RAs as the Preferred Treatment in T2DIn a debate-style session with Dr. Bloomgarden, Dr. Pratley makes a compelling case that GLP1-RAs are the better choice, after metformin, to counter the metabolic abnormalities for which with established type 2 diabetes are at significant risk.

Joshua Beckman, MD, professor of medicine at Vanderbilt University Medical School in Nashville, Tennessee, raised the alarm regarding needed Attention to Peripheral Artery Disease in Diabetes. Up to 33% of patients with diabetes who are screened, present with PAD—an independent predictor of adverse outcomes in people with diabetes—and who face neuropathy, foot deformities and ulcerations, amputation, and increased mortality if not treated.

Mark Kearney, MBCHB, MD, British Heart Foundation Professor of Cardiovascular Medicine and Diabetes Research in Leeds, UK, offered a heart failure treatment path for patients with diabetes. Given the accelerated increase in rates of concomitant diabetes and coronary artery disease, Dr. Kearney urged for aggressive treatment with known tools to lessen chronic heart failure mortality.


Last updated on
First Article From This Meeting:
Diabetes and Cardiovascular Disease Impact Essentially Every Organ in the Body
close X